FDA Brief

Warning letters Drugs

FDA warning letter to

Hangzhou Yiqi Biotechnology Co., Ltd

High riskIssued Apr 15Posted May 19Center for Drug Evaluation and Research (CDER)

FDA cited Hangzhou Yiqi Biotechnology, an API maker in China, for four manufacturing practice failures found in a records review.

What happened

FDA reviewed records the company sent after a June 16, 2025 request for information about its facility (a records request, not an on-site inspection). The records showed no process validation for its active pharmaceutical ingredients, no validation or verification of its test methods, no routine stability testing, and no proof its water system is suitable for use. FDA placed all drugs from the site on Import Alert 66-40 on January 30, 2026, which means shipments can be stopped at the border.

What FDA found

  1. The company never validated its manufacturing processes, so it cannot show it reliably makes API that meets its quality specifications.

    21 U.S.C. 351(a)(2)(B); section 501(a)(2)(B) of the FD&C Act
  2. The company did not validate or verify the test methods it uses to check its drugs, so results given to customers may not be trustworthy.

    21 U.S.C. 351(a)(2)(B); section 501(a)(2)(B) of the FD&C Act
  3. The company has no documented ongoing stability testing program to show its APIs stay within specification through their labeled expiry date.

    21 U.S.C. 351(a)(2)(B); section 501(a)(2)(B) of the FD&C Act
  4. The company did not show that the water used to make its APIs is properly monitored and kept free of contamination.

    21 U.S.C. 351(a)(2)(B); section 501(a)(2)(B) of the FD&C Act

What FDA wants

FDA tells the company to correct the deviations, send a written reply within 15 working days saying what it has done and how it will prevent recurrence, and explain any delays with a completion schedule. FDA also asks for a validation program summary, a stability risk assessment and corrective action plan, water monitoring procedures, and a laboratory assessment.

Who should pay attention

  • drugmakers and compounders that buy API from this firm
  • companies whose applications list this site as an API manufacturer
  • sterile product manufacturers relying on suppliers without process validation

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  3. Sanrace Biotechnology Co., Ltd.

    FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.

    High risk
  4. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk